Thomas N. Chase, M.D.
Affiliations: | National Institutes of Health, Bethesda, MD |
Area:
Parkinson's diseaseGoogle:
"Thomas Chase"Mean distance: 18.7 (cluster 11)
Cross-listing: Neuropathology Tree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chase TN, Clarence-Smith K. (2015) P1-290: High-dose cholinesterase inhibitor treatment of Alzheimer's disease Alzheimer's & Dementia. 11: P466-P467 |
| Vanover KE, Betz AJ, Weber SM, et al. (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacology, Biochemistry, and Behavior. 90: 540-4 |
| Liang ZQ, Wang X, Li LY, et al. (2007) Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum. Journal of Neuroscience Research. 85: 1295-309 |
| Smith CP, Oh JD, Bibbiani F, et al. (2007) Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates. Neuropharmacology. 52: 515-26 |
| Bara-Jimenez W, Dimitrova TD, Sherzai A, et al. (2006) Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1380-3 |
| Bibbiani F, Oh JD, Kielaite A, et al. (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology. 196: 422-9 |
| Bara-Jimenez W, Bibbiani F, Morris MJ, et al. (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 932-6 |
| Bara-Jimenez W, Dimitrova T, Sherzai A, et al. (2004) Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1183-6 |
| Wessell RH, Ahmed SM, Menniti FS, et al. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 47: 184-94 |
| Chase TN. (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism & Related Disorders. 10: 305-13 |